Drug Trial Radar · NCT04902105
Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite
Last checked: Nov 19, 2026Latest source record: Jul 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
May 13, 2021
Primary completion
Jul 6, 2021
Study completion Jul 6, 2021
Sponsor
- Lead sponsor
- Emalex Biosciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Syneos Health; Nuventra, Inc.
- First posted
- May 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center, open-label, fixed sequence, drug-drug interaction (DDI) study in healthy subjects.
Conditions
- Drug Interaction
Interventions
ecopipam HCLDrug
oral tablets
Mefenamic acidDrug
oral capsules
Divalproex Sodium ERDrug
oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of ecopipam in the presence of mefenamic acidTime frame: Up to Day 16
- Cmax of ecopipam in the absence of mefenamic acidTime frame: Up to Day 16
- Cmax of ecopipam in the presence of divalproex sodium ERTime frame: Up to Day 16
- Cmax of ecopipam in the absence of divalproex sodium ERTime frame: Up to Day 16
- AUCinf of ecopipam in the presence of mefenamic acidTime frame: Up to Day 16
- AUCinf of ecopipam in the absence of mefenamic acidTime frame: Up to Day 16
- AUCinf of ecopipam in the presence of divalproex sodium ERTime frame: Up to Day 16
- AUCinf of ecopipam in the absence of divalproex sodium ERTime frame: Up to Day 16
- AUC0-143 of ecopipam in the presence of mefenamic acidTime frame: Up to Day 16
- AUC0-143 of ecopipam in the absence of mefenamic acidTime frame: Up to Day 16
- AUC0-143 of ecopipam in the presence of divalproex sodium ERTime frame: Up to Day 16
- AUC0-143 of ecopipam in the absence of divalproex sodium ERTime frame: Up to Day 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Syneos Health Clinical Research Services, LLC.
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.